supported by the National Basic Research Program of China(973 project,grant number:2014CB542902);Tianjin Hongrentang Pharmaceutical Co.,Ltd.,Tianjin,China(grant number:HX202016)。
Objective: This study aimed to explore the effects of Chinese patent medicine(CPM) in reducing the incidence of major adverse cardiovascular events(MACE) in patients with coronary heart disease(CHD) angina pectoris an...